{"id":"NCT03129321","sponsor":"Mylan Inc.","briefTitle":"Therapeutic Equivalence and Safety of Two Econazole Nitrate Cream, 1% Products in Tinea Pedis","officialTitle":"Clinical Study to Evaluate the Therapeutic Equivalence and Safety of Econazole Nitrate Cream, 1% (Renaissance Pharma, Inc.) to Econazole Nitrate Cream, 1% (Perrigo New York Inc.) in Tinea Pedis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-03-15","primaryCompletion":"2016-11-17","completion":"2016-11-17","firstPosted":"2017-04-26","resultsPosted":"2018-08-02","lastUpdate":"2022-03-07"},"enrollment":876,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Tinea Pedis"],"interventions":[{"type":"DRUG","name":"Econazole Nitrate Cream, 1%","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Test","type":"EXPERIMENTAL"},{"label":"Reference Standard","type":"ACTIVE_COMPARATOR"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"To evaluate the therapeutic equivalence of the Test formulation, econazole nitrate cream, 1% to the Reference product, econazole nitrate cream, 1% in the treatment of tinea pedis.\n\nTo demonstrate the superiority of the Test and Reference (active) treatments over Placebo treatment in patients with tinea pedis.\n\nTo compare the safety of Test, Reference and Placebo treatments in patients with tinea pedis.","primaryOutcome":{"measure":"Proportion of Patients in Each Active Treatment Group Who Are Considered a Therapeutic Cure","timeFrame":"Day 42","effectByArm":[{"arm":"Test","deltaMin":96,"sd":null},{"arm":"Reference Standard","deltaMin":81,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":4},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":351},"commonTop":[]}}